EGFR Cancer Research Results

EGFR, Epidermal Growth Factor Receptor: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-Driver
Type: Oncogene
EGFR (Epidermal growth factor receptor), which belongs to the tyrosine kinase receptor family (RTKs)
Epidermal Growth Factor Receptor (EGFR) is a cell surface protein that plays a crucial role in the regulation of cell growth, survival, proliferation, and differentiation. It is part of the ErbB family of receptors and is activated by binding to its ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α).

-plays a crucial role in regulating cell growth and division.

Many cancers exhibit overexpression of EGFR, which can lead to enhanced signaling and contribute to tumor growth and survival. This overexpression is often associated with aggressive tumor behavior and poor prognosis.
Scientific Papers found: Click to Expand⟱
3603- QC,    Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus
- Review, AD, NA - Review, Diabetic, NA
*MAPK↓, *neuroP↑, *ROS↓, *Akt↓, *PI3K↓, *IL6↓, *TNF-α↓, *VEGF↓, *EGFR↓, *Casp3↓, *Bcl-2↓, *IL1β↓,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB/CCNB1↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
2441- RES,    Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions
- Review, Var, NA
*toxicity↓, *BioAv↝, *Dose↝, *hepatoP↑, *neuroP↑, *AntiAg↑, *COX2↓, *antiOx↑, *ROS↓, *ROS↑, PI3K↓, Akt↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, NRF2↑, GPx↑, HO-1↑, BioEnh?, PTEN↑, ChemoSen↑, eff↑, mt-ROS↑, Warburg↓, Glycolysis↓, GlucoseCon↓, GLUT1↓, lactateProd↓, HK2↓, EGFR↓, cMyc↓, ROS↝, MMPs↓, MMP7↓, survivin↓, TumCP↓, TumCMig↓, TumCI↓,
2440- RES,    Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway
- in-vitro, Lung, H460 - in-vivo, Lung, NA - in-vitro, Lung, H1650 - in-vitro, Lung, HCC827
AntiTum↑, Glycolysis↓, HK2↓, EGFR↓, Akt↓, ERK↓, GlucoseCon↓, lactateProd↓, TumCG↓, Ki-67↓,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3016- RosA,    Rosmarinic Acid Inhibits Cell Growth and Migration in Head and Neck Squamous Cell Carcinoma Cell Lines by Attenuating Epidermal Growth Factor Receptor Signaling
- in-vitro, HNSCC, UM-SCC-6 - in-vitro, HNSCC, UM-SCC-10B
chemoP↓, EGF↓, tumCV↓, TumCMig↓, ROS↓, PI3K↓, Akt↓, ERK↓, antiOx↑, p‑EGFR↓,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1460- SFN,    High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells
- in-vitro, Lung, NA
ROS↑, EGFR↓, eff↓, TumCCA↑, γH2AX↑, DNAdam↑, eff↓,
1458- SFN,    Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma
- Review, Bladder, NA
HDAC↓, eff↓, TumW↓, TumW↓, angioG↓, *toxicity↓, GutMicro↝, AntiCan↑, ROS↑, MMP↓, Cyt‑c↑, Bax:Bcl2↑, Casp3↑, Casp9↑, Casp8∅, cl‑PARP↑, TRAIL↑, DR5↑, eff↓, NRF2↑, ER Stress↑, COX2↓, EGFR↓, HER2/EBBR2↓, ChemoSen↑, NF-kB↓, TumCCA?, p‑Akt↓, p‑mTOR↓, p70S6↓, p19↑, P21↑, CD44↓, CSCs↓,
3331- SIL,    The clinical anti-inflammatory effects and underlying mechanisms of silymarin
- Review, NA, NA
*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,
3323- SIL,    Anticancer therapeutic potential of silibinin: current trends, scope and relevance
- Review, Var, NA
Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2370- SK,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
Glycolysis↓, PKM2↓, EGFR↓, PI3K↓, p‑Akt↓, Hif1a↓,
2194- SK,    Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706 - in-vivo, NA, NA
tumCV↓, TumCCA↑, Apoptosis↑, EGFR↓, PI3K↓, Hif1a↓, PKM2↓, cycD1/CCND1↓, AntiTum↑,
2188- SK,    Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment
- Review, Var, NA
ROS↑, EGFR↓, PI3K↓, Akt↓, angioG↓, Apoptosis↑, Necroptosis↑, GSH↓, Ca+2↓, MMP↓, ERK↓, p38↑, proCasp3↑, eff↓, VEGF↓, FOXO3↑, EGR1↑, SIRT1↑, RIP1↑, RIP3↑, BioAv↓, NF-kB↓, Half-Life↓,
3043- SK,    Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells.
- in-vitro, Melanoma, RPMI-8226
IGF-1↓, Apoptosis↑, TumCCA↑, MMP↓, Casp3↑, P53↑, BAX↑, Mcl-1↓, EGFR↓, Src↑, KDR/FLK-1↓, p‑IGF-1↓, PI3K↓, Akt↓,
5102- SK,  GEM,    Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway
TumCG↓, ChemoSen↑, NF-kB↓, PCNA↓, Ki-67↓, p‑EGFR↓, ROS↑, TumCCA↑, P53↑, JNK↑, Akt↓,
2010- SK,    Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
- in-vitro, Lung, H1975 - in-vitro, Lung, H1650 - in-vitro, Nor, CCD19
EGFR↓, selectivity↑, Casp↑, PARP↑, Apoptosis↑, ROS↑, eff↓, selectivity↑,
1575- statins,  Citrate,    Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways
- in-vitro, NSCLC, A549
eff↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,
3413- TQ,    Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase
- in-vitro, CRC, HCT116
tumCV↓, Apoptosis↓, BAX↑, Bcl-2↓, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, STAT3↓, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, EGFR↓, ROS↑,
2411- UA,    Ursolic acid in health and disease
- Review, Var, NA
Inflam↓, antiOx↑, NF-kB↓, Bcl-xL↓, Bcl-2↓, cycD1/CCND1↓, Ki-67↓, CD31↓, STAT3↓, EGFR↓, P53↑, P21↓, HK2↓, PKM2↓, ATP↓, lactateProd↓, p‑ERK↓, MMP↓, NO↑, ATM↑, Casp3↑, AMPK↑, JNK↑, FAO↑, FASN↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑, neuroP↑,
2414- β‐Ele,    Beta‐elemene inhibits breast cancer metastasis through blocking pyruvate kinase M2 dimerization and nuclear translocation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumMeta↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PKM2↓, EGFR↓, GLUT1↓, LDHA↓, ECAR↓, OCR↓,

Showing Research Papers: 101 to 125 of 125
Prev Page 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 125

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   CYP1A1↓, 1,   GPx↑, 1,   GSH↓, 2,   GSH↑, 1,   HO-1↑, 1,   MDA↓, 1,   NRF2↑, 4,   mt-OXPHOS↓, 1,   ROS↓, 4,   ROS↑, 12,   ROS↝, 1,   mt-ROS↑, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 3,   EGF↓, 2,   FGFR1↓, 1,   MMP↓, 8,   OCR↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

p‑ACLY↓, 1,   AKT1↓, 1,   AMPK↑, 1,   cMyc↓, 5,   ECAR↓, 1,   FAO↑, 1,   FASN↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 5,   HK2↓, 4,   HMG-CoA↓, 1,   lactateProd↓, 4,   LDH↑, 1,   LDHA↓, 1,   PKM2↓, 4,   SIRT1↓, 1,   SIRT1↑, 1,   SREBP1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 10,   p‑Akt↓, 5,   Apoptosis↓, 1,   Apoptosis↑, 7,   Bak↑, 1,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 4,   Bcl-xL↓, 1,   BID↑, 1,   Casp↑, 2,   Casp3↓, 2,   Casp3↑, 7,   proCasp3↑, 1,   Casp7↑, 2,   Casp8∅, 1,   Casp9↑, 5,   cFLIP↓, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 5,   Diablo↑, 1,   DR5↑, 2,   FasL↑, 1,   hTERT/TERT↓, 1,   iNOS↓, 2,   JNK↑, 2,   MAPK↓, 3,   MAPK↑, 1,   Mcl-1↓, 1,   Necroptosis↑, 1,   p27↑, 3,   p38↑, 2,   RIP1↑, 1,   survivin↓, 5,   Telomerase↓, 1,   TRAIL↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 3,   p70S6↓, 1,  

Transcription & Epigenetics ⓘ

ac‑H3↑, 1,   ac‑H4↑, 1,   HATs↓, 1,   HATs↑, 1,   miR-21↓, 1,   miR-21↑, 1,   p‑pRB↓, 2,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,   HSP70/HSPA5↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3B-II↑, 1,  

DNA Damage & Repair ⓘ

ATM↑, 1,   DNAdam↑, 1,   DNMT1↓, 1,   DNMTs↓, 1,   P53↑, 7,   PARP↓, 1,   PARP↑, 1,   cl‑PARP↑, 3,   PARP1↑, 1,   PCNA↓, 3,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK2↑, 1,   CDK4↓, 3,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 7,   cycE/CCNE↓, 1,   E2Fs↓, 1,   p19↑, 1,   P21↓, 1,   P21↑, 4,   RB1↑, 1,   TumCCA?, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 2,   CSCs↓, 2,   EMT↓, 6,   ERK↓, 6,   ERK↑, 1,   p‑ERK↓, 2,   FGF↓, 1,   FGF↑, 1,   FOXO3↑, 1,   Gli1↓, 1,   HDAC↓, 4,   IGF-1↓, 1,   p‑IGF-1↓, 1,   IGFBP3↑, 2,   mTOR↓, 1,   p‑mTOR↓, 2,   NOTCH↓, 2,   NOTCH1↓, 1,   PI3K↓, 11,   PTEN↑, 2,   RAS↓, 1,   Shh↓, 2,   Smo↓, 1,   Src↑, 1,   STAT3↓, 4,   p‑STAT3↓, 1,   STAT5↓, 1,   TumCG↓, 4,   Wnt↓, 3,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

Akt2↓, 1,   AntiAg↓, 1,   AP-1↓, 1,   CA↓, 1,   Ca+2↓, 1,   Ca+2↑, 1,   CD31↓, 1,   CLDN2↓, 1,   CXCL12↓, 1,   E-cadherin↑, 3,   FAK↓, 2,   Ki-67↓, 4,   miR-155↓, 1,   miR-203↑, 1,   MMP2↓, 6,   MMP7↓, 1,   MMP9↓, 6,   MMPs↓, 3,   MUC1↑, 1,   N-cadherin↓, 1,   PDGF↓, 2,   PKCδ↓, 1,   RIP3↑, 1,   Slug↓, 1,   Snail↓, 3,   TGF-β↓, 3,   TIMP1↑, 1,   TSP-1↑, 2,   TumCI↓, 4,   TumCMig↓, 6,   TumCP↓, 3,   TumMeta↓, 4,   uPA↓, 3,   uPAR↓, 1,   Vim↓, 2,   Zeb1↓, 3,   α-SMA↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 6,   EGFR↓, 19,   p‑EGFR↓, 4,   EGR1↑, 1,   HIF-1↓, 1,   Hif1a↓, 7,   KDR/FLK-1↓, 1,   LOX1↓, 1,   NO↓, 1,   NO↑, 1,   VEGF↓, 7,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

GLUT1↓, 2,   NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 7,   CRP↓, 1,   CXCR4↓, 2,   IFN-γ↓, 1,   IL1↓, 2,   IL10↓, 2,   IL1β↓, 2,   IL6↓, 3,   Inflam↓, 3,   JAK2↓, 2,   NF-kB↓, 11,   PD-L1↓, 2,   PGE2↓, 1,   PSA↓, 2,   TLR4↓, 1,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↝, 2,   BioEnh?, 1,   ChemoSen↑, 5,   Dose↝, 2,   eff↓, 6,   eff↑, 9,   eff↝, 1,   Half-Life↓, 2,   Half-Life↝, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 2,   CRP↓, 1,   EGFR↓, 19,   p‑EGFR↓, 4,   GutMicro↝, 1,   HER2/EBBR2↓, 3,   hTERT/TERT↓, 1,   IL6↓, 3,   Ki-67↓, 4,   LDH↑, 1,   PD-L1↓, 2,   PSA↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 3,   cardioP↑, 1,   chemoP↓, 1,   chemoP↑, 2,   hepatoP↑, 2,   neuroP↑, 1,   toxicity↝, 1,   toxicity∅, 1,   TumW↓, 2,  
Total Targets: 251

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   GSTs↑, 1,   lipid-P?, 1,   lipid-P↓, 1,   ROS↓, 3,   ROS↑, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Bcl-2↓, 1,   Casp3↓, 1,   iNOS↓, 1,   MAPK↓, 2,   p38↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,   PI3K↓, 1,  

Migration ⓘ

5LO↓, 1,   AntiAg↑, 1,   TIMP1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 2,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 3,   NF-kB↓, 1,   TNF-α↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   Dose↝, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   hepatoP↑, 1,   neuroP↑, 3,   toxicity↓, 3,  
Total Targets: 40

Scientific Paper Hit Count for: EGFR, Epidermal Growth Factor Receptor
11 Fisetin
10 Quercetin
9 Curcumin
9 EGCG (Epigallocatechin Gallate)
8 Honokiol
6 Shikonin
5 Silymarin (Milk Thistle) silibinin
4 almonertinib
4 Berberine
3 Artemisinin
3 Bufalin/Huachansu
3 brusatol
3 Luteolin
3 Resveratrol
3 Sulforaphane (mainly Broccoli)
2 Alpha-Lipoic-Acid
2 Apigenin (mainly Parsley)
2 Betulinic acid
2 Brucea javanica
2 cetuximab
2 Docetaxel
2 Ursolic acid
2 Gallic acid
2 Graviola
2 Magnetic Fields
2 Piperlongumine
1 Astragalus
1 Silver-NanoParticles
1 Allicin (mainly Garlic)
1 Ashwagandha(Withaferin A)
1 Astaxanthin
1 Aloe anthraquinones
1 Biochanin A
1 Chemotherapy
1 Boron
1 Capsaicin
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Carvacrol
1 Thymol-Thymus vulgaris
1 Chlorogenic acid
1 Chrysin
1 Photodynamic Therapy
1 gefitinib, erlotinib
1 Deguelin
1 Ellagic acid
1 Piperine
1 Gambogic Acid
1 Licorice
1 Lycopene
1 Myricetin
1 Naringin
1 Niclosamide (Niclocide)
1 Phenethyl isothiocyanate
1 Gold NanoParticles
1 Rosmarinic acid
1 Gemcitabine (Gemzar)
1 statins
1 Citric Acid
1 Thymoquinone
1 β‐Elemene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:94  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page